Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
RSVPreF3 OA Investigational Vaccine in Indian Adults at Risk of RSV-LRTD
NCT06614725Phase 3Completed
- Sponsor
- GSK
- Start
- Oct 2024
- Primary completion
- Jun 2025
- Modality
- Vaccines & Immunotherapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of GSK3003899A in respiratory syncytial virus infection (RSV), sponsored by GSK. Started Oct 2024; status: completed.
02
Drugs
GSK3003899A
03
Conditions
respiratory syncytial virus infection (RSV)
Beyond the preview
Go deeper on NCT06614725.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06614725.